Maronde R F, Chan L S, Vlachakis N
Am J Cardiol. 1986 Jul 31;58(2):18A-21A. doi: 10.1016/0002-9149(86)90878-7.
Potassium supplementation in diuretic-induced hypokalemia (serum potassium less than 3.5 mmol/liter) in patients being treated for hypertension is a common event. In a previous study 40 mmol/day of orally administered potassium was not effective in preventing diuretic-induced hypokalemia in patients who had previously developed hypokalemia while being treated for hypertension with hydrochlorothiazide. In the study reported here dosages as high as 60 to 80 mmol/day of orally administered potassium failed to prevent hypokalemia in 7 of 19 hypertensive patients who were receiving hydrochlorothiazide. Potassium supplementation was compared with the potassium-sparing diuretic amiloride. The study design was open label and subject matched with crossover of therapeutic regimens.
在接受高血压治疗的患者中，补充钾以治疗利尿剂诱发的低钾血症（血清钾低于3.5 mmol/升）是常见的情况。在先前的一项研究中，对于那些在使用氢氯噻嗪治疗高血压期间曾出现低钾血症的患者，每天口服40 mmol钾并不能有效预防利尿剂诱发的低钾血症。在本报告的研究中，19名接受氢氯噻嗪治疗的高血压患者中有7名，即使每天口服高达60至80 mmol的钾也未能预防低钾血症。将补充钾与保钾利尿剂阿米洛利进行了比较。研究设计为开放标签且受试者匹配治疗方案交叉设计。
